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BIOTECHNOLOGY: ANCIENT AND MODERN 
Louis Pasteur wrote "There are no applied sciences; there are only 
applications of science...The study of the application of science is very easy 
to anyone who is master of the theory". A few years later Lord Kelvin 
instructed us that "If you can measure that of which you speak, and can 
express it by a number, you know something of your subject. But if you cannot 
measure it, your knowledge is meagre and unsatisfactory." It would indeed be 
interesting to know what the spirits of these distinguished scientists are 
thinkinq about "Biotechnology" which takes within its broad embrace remarkable 
new knowledge in cell and molecular biology; some very ancient technologies; 
together with a large swatch of enpirical observations and discoveries, many 
of which remain far distant from viable technological application. 
Fermentation technologies have a very long history: beer, wine, bread 
and cheese having been around as long as cereals and vine fruits have been 
harvested and animais have been milked. Homer described wine as a qift from 
the Gods and Ecclesiasticus wisely advised that "From the beginning wine was 
created to make men joyful, not to make them drunk." 
Though ethanolic fermentations have been most pervasive, lactic and other 
acidic fermentations have appeared in greater diversity, particularly in 
traditional domestic processes of preservation. The ancient Sumerians 7,000 
years ago converted all their milk into cheese in the stated belief that had 
God intended mankind to have clean milk to drink he would have placed the 
udders at the front end of the cow. /Î 
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In addition to the hundreds of cheese varieties, buttermilk, cour milk 
and yogurt, with which all Americans and Europeans are familiar, other lactic 
milk products include kefir, koumiss and vilia in the Slavic and Scandinavian 
countries. Egyptian kishk, Greek trahana, Indian idli, Nigerian oqi, Kenyan 
ugi and South African majou are but a few of many lactic-cereal ferments. 
Lactic vegetable pickles have been eaten in the Middle East and throughout 
much of Asia for as long as we have historical record. Lactic acid as such 
has been manufactured in the United States for more than 100 years. 
Acid fermentation of milk, vegetables, fish and meat are among the most 
widely applied and trusted methods of preservation in many Asian tropical 
countries. Though the lowerinq of pH to levels at which pathogens will not 
grow and the generation of hydrogen peroxide and the antibiotic nisin by Lacto 
bacilli are well-known to food technologists, the systematic industrialization 
of traditional fermentation industries in Asia has been less extensive than 
might have been expected. Perhaps the revived interest in biotechnology and 
fermentation systems will serve to change this situation in the future. 
Though nome would have us helieve to the contrary, the word 
"Biotechnology" is far from new. A Bureau of Biotechnology existed in Leeds 
over half a century ago, the first copy of the Bulletin of the Bureau of 
Biotechnology beinq published in July 1920. This Bureau metamorphosed out of 
a consultinq practice which was publishing papers on brewinq and other 
fermentation technologies as early as 1899. The Leeds consultant laboratory 
was among the first to provide industrial consultant services in both 
chemistry and microbiology. 
UMIST and its related institution along Oxford Street have distinguished 
records in fermentation biochemistry. Or. Thomas Kennedy Walker welcomed the 
first students to his new Department of Fermentation Industries in this 
Institution in 1923. Walker later changed the name of the department to 
"Industrial Biochemistry", which semantically seems little different from 
"Biotechnology". The imaginative pioneering contribution which Professor 
Walker made to the foundation of food science and the training of so many of 
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its early practioners in Britain has never been adequately recognized. His 
former students are to be found in bioloqical research institutions and 
industries not only in Britain but throughout a qreat many developing 
countries. 
During his life in Manchester, T.K. Walker and his graduate students 
published more than 170 papers coverinq a fascinatinq range of applied 
microbiology and fermentation technologies. In light of the renaissance of 
industrial microbiology within the family of contemporary biotechnologies, 
Walker's pioneerinq work deserves to be revisited by present day practioners. 
One of Professor Walker's distinquished colleaques was Dr. James Mounfield, the 
founding father of the IFST who made many important contributions to our 
knowledge of panary fermentation. 
In 1909 in Manchester University, to which he had moved from Geneva in 
1904, Chaim Weizmann, working under Perkin, began his search for a bacterial 
strain that would convert carbohydrate to iso-amyl alcohol, a precursor via 
isoprene of synthetic rubber. Instead, in 1912, he isolated the strain of 
Clostridium acetobutylicum which converts carbohydrate into butanol, acetone 
and ethanol in the ratio of 6:3:1. The process was extensively used to 
produce the acetone needed by the military to plasticize cordite during the 
First World War. Follo wing WWI butanol gained wide acceptance in lacquers for 
automobiles. Weizmann's acetone-butanol process and Walker's elucidation of 
the role of the polyphenolic antiseptics, lupulone and hunulone, are of 
contemporary importance to the organic chemical and brewing industries 
respectively. 
Elsewhere I have attempted a more comprehensive review of the state of 
the biotechnological art (IDRC, 1985) and of the history of biotechnology in 
the food industries (Hulse, 1984; Hulse, 1985). The scope of this 
presentation will permit little more than a superficial overview of some of 
the more interesting developments as they relate to agriculture, food, human 
and animal health. In conclusion I shall attenpt to address what I see as some 
4 
important implications for humanity in general together with some particular 
issues of concern to academic institutions, industrial organizations and 
developing countries. 
CONTEMPORARY BIOTECHNOLOGY 
The more enthusiastic advocates of biotechnology would have us believe 
that the potentiel applications of rDNA techniques for human benefit are 
limited only by the imaginations of those who seek to manipulate and apply 
them to industrial and commercial use. Nevertheless, experience suggests, 
particularly in the medical field, that hoped for benefits may well be more 
elusive than originally anticipated. 
The uncertainties attendant upon the new biotechnologies are such that 
future market prospects cannot be reliably forecast by econometric or other 
predictive methods. In spite of the immense interest aroused b y the 
remarkable, and for the most part favorable, publicity the sub,iect has 
received, with the possible exception of Japan few nations seem to have 
established well-defined and coordinated programs for bioscientific research 
and biotechnoloqical development. 
Though, theoretically, a biotechnology could be elaborated for any 
industrial process in which a bioloqical catalyst or process of transformation 
can replace one based on chemistry, greatest investment and probably most 
progress will be in the biomedical field, in large part because pharmaceutical 
products carry a high value added and can be arbitrarily priced to recover the 
cost incurred in research, development, manufacture and distribution. In 
spite of George Bernard Shaw's warning to the contrary, most of us would like 
to live forever and there seems almost no limit to what wealthier nations will 
pay to protect their health and to lenqthen their lifespan. Thus the colt of 
a biotechnology congenial to a pharmaceutical manufacturer could quickly 
bankrupt a food processor. 
It now seems acceptable to separate the subject into (a) the old and 
traditional and (b) the new or contenporary biotechnoloqies. If for 
convenience we accept this categorization, the following is a chronological 
calendar of conteîporary biotechnology. 
1953 the twin helix of DNA was described. 
1973 the first gene was cloned. 
1974 a cloned gene was first expressed in a different bacterial 
species. 
1975 the first hybridoma was created. Also at the Asilomar Conference, the 
U.S. formulated its first safety guidelines for rDNA research. 
1976 GENENTECH was the first U.S. company founded to explore and exploit rDNA 
research. 
1976 the U.K. Government established the Genetic Manipulation Advisory Group 
(GMAG). 
1980 the U.S. Supreme Court ruled that microorganisms could he patented under 
existinq law. 
1980 GENENTECH's first public stock offering recorded the fastest price per 
share increase on record. The price rose from $35.00 to $89.00 per 
share in 20 minutes. 
1981 CETUS established a Wall Street record by raisinq US$115 M in its 
initial public stock offering. 
END OF 
1981 more than 80 new biotechnology companies had been formed in the U.S.A. 
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1982 the first rDNA animal vaccine for colibacillosis was approved for use in 
Europe and the first rDNA pharmaceutical (human insulin) approved for 
use in the U.S. and the U.K. 
The vast array of new industrial processes forecast by the more ardent 
advocates of modern biotechnology are fascinating indeed. One is reminded of 
the enthusiasm for nuclear fission 25 years ago promising irradiation 
technologies to generate an infinite variety of new plant mutants; total 
sterilization and disinfestation of perishable foods; a limitless supply of 
energy independent of fossil fuels. Once again scientific imagination may 
have to be tempered by economic pragmatism. 
It is conceivable that a variety of microorganisms and plant tells could 
be genetically engineered to qenerate new orqanic compounds as starting 
materials for further chemical synthesis. Outside of the pharmaceutical and 
fine chemical fields such dues not seem to be imminent, probably because of 
the high cost of research and scale-up compared with established industrial 
organic chemical synthetic processes. 
FOOD & DRUGS 
While in legislative protocols food and drugs usually walk hand in hand, 
biotechnoloqy in food processinq long predates its establishment in 
pharmaceutical industries. Nevertheless in contenporary biolotechnology, 
levels of investment in food and pharmaceutical research are of very different 
orders of magnitude. Rouqhly 75% of U.S. Government investment in 
biotechnology research is directly related to the health sciences. The 
largest multinational pharmaceutical companies invest more than 12% of their 
sales income in research. Hoffmann-Laroche reputedly invests 13.8%. In 
comparison food industries in Canada invest less than 0.2% of sales on 
research. The total world value of pharmaceuticals and related health 
chemicals is estimated close to US$100 B of which the U.S. consumes about 
10%. 
Close to 20% of all drugs are derived wholly or partially from 
microorganisms, antibiotics beinq the largest single clans of 
microbiologically derived druqs. Alexander Fleming's discovery in 1928 that 
Penicillium notatum destroyed cultures of Staphylococcus aureus led to the 
eventual isolation by Florey of penicillin. About 300 new antibiotics are 
reported every year, most being isolated from Streptomyces species of 
Actinomycetes. 
Over the past quarter century fermentor yields of penicillin have 
increased from a few milligrams to over 20 g/l. These increased yields have 
resulted from the selection of superior strains among random mutants together 
with significant improvements in fermentor design and operation. In the 
foreseeable future further improvements in antibiotic production will more 
likely result from established industrial microbiological procedures than from 
genetic engineering. Syntheses of primary proteins are largely controlled by 
single genes, whereas antibiotics and other secondary metabolites require 
expression of up to 30 genes. Nevertheless, some progress has been reported 
in qenerating new and modified antibiotics through protoplast fusion of 
different Streptomyces species. 
The large pharmaceutical companies require between 8 and 10 years and up 
to US$100 M of investment to brinq each new drug to the market. The larqer 
U.S. companies employ sales forces of 500 or more to convince medical and 
pharmaceutical professionals of the merits of their products. Despite these 
large R&D commitments fewer new drug introductions appear now than in former 
years. The contributinq constraints include: more rigorous government 
legislation; relatively short periods or inadequacy of patent protection for 
new drugs; competition from qeneric and "no-name" products sold at lower cost 
than the established name brands. Though biotechnology seems unlikely in the 
near term to reduce the high costs of marketing and distribution, new 
techniques will probably reduce research and development time for biological 
screening, pharmacoloqical testinq and clinical evaluation. 
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Pharamcological effectiveness requires the precise correlation of 
physiological function with molecular structure. Accurate determination of 
the structure of drug receptor molecules in living organisms by gene cloning 
and DNA sequencing research will likely define the biochemical structure of 
new drugs that will react effectively with identified receptors. The 
integration of computers with these novel and elegant techniques offers a more 
expeditious means of arriving at chemical structures which provide the potency 
and effectiveness desired. The potentiel spinoff for nutritional and food 
biochemistry, thouqh not immediately evident, is nonetheless a distinct 
possibility. 
If novel biotechnological techniques can reduce the cost of research and 
development substantially, the pharmaceutical industries may be more disposed 
in the future than in the past to address nome of the serious tropical 
infectious diseases that debilitate millions of people in developing 
countries. There is, however, the danger that drugs and other biological 
materials may be released into countries where protocols and regulatory 
mechanisms for ensuring safety do not exist or are not rigorously applied. 
The International Organization of Consumers Unions (IOCU) has repeatedly drawn 
attention to the sale in developinq countries of drugs that are restricted or 
banned in the more advanced nations in which they are manufactured. The IOCU 
reports that anabolic steroids and other dangerous drugs may be bought without 
medical prescription across the counter in many developing countries. 
ANIMAL PRODUCTION 
Of particular interest to food and agricultural scientists are the 
various hormones that regulate reproductive physiology and rates of growth. 
The value of animal growth hormones is estimated at US$500 M annually, half of 
which are used in the United States. Throughout the world the employment of 
animal growth hormones is increasing at a compound annual growth rate of 25%. 
GENENTECH, in cooperation with Monsanto, are producing a variety of animal 
growth hormones by rDNA techniques. In addition, growth hormone research is 
examining the complex nature of growth development and animal productivity. 
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Injections of purified growth hormones can increase milk production by up 
to 17% without change in feed intake. Sheep and hogs show rapid growth and 
improved feed conversion eff i ci ency fol l owi ng GH treatment. However, the 
long-term effects of GH administration on the health of animais to which they 
are administered and upon consumera is causinq growing concern. Of particular 
concern to food technologists is the influence of GH treatment upon carcass 
quality. 
Various microbially derived products are being examined to improve feed 
efficiency: some destroy or inhibit bacterial, protozoal or other parasitic 
organisms in the GI tract; others stimulate the growth of beneficial 
microorganisms in the gut. The possibility that rDNA-derived, highly 
resistant pathogenic organisms spread from animal faeces may present a serious 
public health hazard is not to be treated lightly. Consequently, more 
research and reliable control protocols are required before products that 
significantly alter intestinal flora can be permitted for widespread use. 
Following the widely publicized transfer of rat growth hormones into mice 
and because the injection of growth hormones derived from industrial 
fermentations may carry with them unwanted pathogens, research is in progress 
to insert growth hormone genes into animal genomes. 
The high cost of deep-sea fishing caused b.y escalating prices of 
transportation fuels has stimulated investment in fish culture. Commercial 
fish culture requires, first, the production of gametes from brood stock, 
followed by the rearing of the resultant offspring to healthy fish of 
marketable size. Selective breeding for more efficient feed conversion 
requires several generations and many years of research, and the time taken to 
reach economic size and weight is, for many species, uneconomic. 
Scientists in Canada report that inoculation with the natural growth 
hormone extracted from the pituitaries of bovines and pouitry significantly 
increases specific growth rate and feed conversion in Cohoe salmon. The genes 
that regulate the production of growth hormones in both pouitry and bovines have 
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been transferred by a plasmid vector into E. coli. Satisfactory expression of 
the cloned genes resuits in the microbial generation of biologically active 
recombinant growth hormones which, it is anticipated, will be satisfactorily 
used to increase the rate of growth of both juveniles and adult Salmonids thus 
reducing the time and colt of production. 
Of equal interest is the hormonal control of reproductive systens in both 
terrestrial and aquatic animais of economic importance. Research supported by 
IDRC in several Asian countries has demonstrated how qonadotropins extracted 
from the pituitaries of Pacific salmon and Asian carp can induce gravid 
female fish to lay their eggs which they are often reluctant to do when held 
in captivity. 
Hormone-induced super-ovulation in domestic cattle is gaininq increased 
recognition in animal production systems. The hormone is impregnated onto a 
vaginal tampon. Super-ovulation by growth hormones may trigger the release of 
between 10 and 20 eggs per year, makinq possible large numbers of genetically 
superior offsprinq from elite cows. These embryos can be twinned to produce 
identical individual calves. In practice, one embryo can be implanted in a 
surrogate mother cow, the twin embryo being frozen until the implanted embryo 
demonstrates the viability and superiority expected of it. In many instances, 
a transplanted embryo carries with it the immunities from its genetic origin 
and then acquires the environmental immunities from its surrogate mother. 
The International Laboratory for Research on Animal Diseases (ILRAD, 
1985) is working to reduce the incidence of trypanosomiasis, a protozoal 
disease which induces severe morbidity and mortality among cattle over an area 
of Africa equal to that of the United States. The N'Dama cattle in Gambia 
show significantly greater resistance to trypanosomiasis than many other 
breeds. ILRAD has induced ovulation in N'Dama cows, transported the embryos 
in the frozen state before implantation in Kenya into trypanosome-susceptible 
Boran cows. The cryogenic techniques available permit the preservation of up 
to 100 embryos which can be stored and transported in a container no larger 
than a suitcase. 
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Some observera suggest that genetically derived vaccines for animais 
offer greater potential profit to manufar_turers than those for humans. It is 
argued that to acquire immunization, human beings require relatively few and 
infrequent doses of potent vaccines. In contrast, farm animais are 
continuously slaughtered and therefore each new animal needs individual 
immunization. It has also been suggested that safety requirements for animal 
vaccines are less exacting and therefore the cost of bringing them to market 
is lower than for human vaccines. 
Though this argument is of dubious validity, given the high price that 
wealthy nations will pay for pharmaceuticals that may control cancer and other 
fatal maladies, research is in progress to produce vaccines for various animal 
diseases amonq which Foot-and-Mouth Disease ranks high in importance. More 
than 800 M doses of attenuated FMD virus vaccine worth over US$250 M are 
administered annually. The FMD vaccines available vary considerably in their 
effectiveness against different viral strains. GENENTECH, in collaboration 
with the U.S. Department of Agriculture, claims to have cloned into a 
bacterium the DNA that encodes the protein for one important strain of FMD. 
The vaccine has heen produced in sufficient quantities for field trials to 
determine how broad is its spectrum of effectiveness. 
If the generation of rDNA derived vaccines for viral diseases appears 
difficult, those for bacterial and protozoal infections are infinitely more 
so. The protozoa which cause trypanosomiasis carry their antigens as 
glycoproteins on their surface coatings. Each antibody developed by the 
animal's immune system acts to neutralize a specific trypanosome antigen. At 
least 100 genes are at work continuously modifying the chemical structure of 
the antigens. The animal's defensive mechanism is thus rarely able to keep up 
with the continuous change in antigen structure. Consequently, the hope for 
vaccines that will confer permanent immunity against protozoal diseases 
appears remote in the near future. 
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ANALYTICAL AND DIAGNOSTIC TOOLS 
Recombinant DNA technology is however providing important diagnostic 
tools both for human and animal diseases. The production and application of 
murine monoclonal antibodies has been sufficiently well publicized to need no 
description. An equally important diagnostic tool is DNA hybridization which 
occurs when two separate single strands of DNA join to reform the double 
helix. The two strands must have exact corresponding sequences of nucleotide 
bases for hybridization to occur. A qiven strand can hybridize only with its 
complementary strand. Radioactive phosphorus is being incorporated into the 
DNA strand known as the "probe". Hybridization, when it occurs, can be 
followed by the radioactive label. 
DNA hybridization probes can be used to identify and isolate particular 
DNA sequences and to determine where certain DNA sequences are located on 
particular chromosomes. A probe-DNA isolated from a pathogenic virus can be 
used to identify that virus within plant or animal cells thus making possible 
specific diagnosis. DNA hybridization probes offer more precise methods of 
diagnosing infections and of identifying specific DNA sequences in naturally 
occurring and synthesized biological materials. 
PLANT CELL AND TISSUE CULTURE 
It is 125 years rince Gregor Mendel uncovered the patterns of inheritance 
displayed in the progeny of genetically different plant parents. Mendel's 
elucidation of how characters are combined and inherited provided the basic 
for all subsequent plant and animal breeding. 
Conventional plant breedinq proceeds through collection, classification, 
selection, combination, recombination and propagation. Germplasm collection 
seeks to bring together a smorgasbord of genotypes, embodying a broad range of 
identifiable and inheritable characters. From these are selected plants which 
display desirable characters. Where all the characters desired are not found 
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in a single genotype, sexual cross-breeding seeks to combine the desirable 
characters from different parents. Desirable characters not found in the 
germplasm bank may be introduced by accessioning wild relatives or by induced 
mutation. Unfortunately, mutation induced by irradiation or chemical mutagens 
is quite unpredictable and uncontrollable. 
The ultimate plant breeding objective is to generate pure lines: 
cultivars that are genetically stable and homozygous, having inherited 
identical chromosomes from both parents. To achieve homozygosity so that a 
plant carrying a combination of desired characters will breed true, requires 
that the cultivar be "selfed": that it be fertilized with its own pollen 
through five or six succeeding generations. This long and tedious procedure 
explains why it takes 8 to 15 years to develop new cereal varieties to the 
stage at which they can reliably be licensed. Once a homozygous pure breeding 
line has been realized its seed must be multiplied into quantities sufficient 
for commercial distribution, another time-consuming procedure. 
Plant cell and tissue culture provide means of short circuitinq and 
reducing the time required for many of these conventional processes, in 
addition to providing the basis for a new generation of industrial biological 
technologies. 
Cell culture is based upon totipotency: the biological phenomenon 
whereby every somatic, non-sexual cell embodies a twin pair of chromosomes 
each carryinq all the several million qenes the plant needs for systematic 
growth, metabolism and other essential functions. Theoretically, every 
somatic cell is capable of producing a whole new plant if appropriately 
cultured. If this were invariably so, one cm3 of vegetative tissue could 
generate about one million identical plant clones. In fact, at best, 
relatively few cells will yi?ld new viable plants when cultured. 
Plant cells, like microorganisms, can be cultured in nutrient broth or 
solid media. The processes are as yet empirical and, according to the source 
of the tissue cells, the composition of the medium, and the ambient conditions 
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the cells may proliferate into a callus: a mass of undifferentiated cells; or 
into an orqanized differentiated pattern so arranged as to form a small plant 
with a shoot and a root. In some instances, progressive sub-cultures of 
primary callus in differing concentrations of the plant growth hormones, 
auxins and cytokinins will stimulate successively the émergence of a shoot and 
a root. The advantages of tissue culture include: 
(1) propagation of large numbers of plants from a single superior parent; 
(2) generation of disease-free plants from infected parents; 
(3) generation of plants difficult to propagate sexually. 
The time-consuming process of generating pure in-bred lines has been 
described. Every sexual cell, whether from pollen or ovaries, contains a 
single set of chromosomes. Consequently, plants propagated from pollen or 
anthers will be sterile and incapable of reproducing themselves. By treatment 
of the anther culture with colchicine, an alkaloid extracted from the autumn 
crocus, each single chromosome will double, the second chromosome being 
identical to the first. In this way homozygous pure breeding lines can be 
generated, eliminatinq many years of self-pollination. 
Canadian plant breeders are enployinq pollen culture to produce superior 
elite lines of rapeseed, combining high yield potential with lover erucic acid 
and glucosinolate contents. The technique offers the early realization of 
superior lines of several tropical legume crops. It is also reported that 
anther culture has produced viable, genetically stable, homozygous pure lines 
of barley, rice, rye and wheat. 
Oil palm is a naturally outbreeding species. Consequently, the breeding 
stock carries a high incidence of heterozygosity and progeny display 
significant variance in identifiable genetically controlled characters. 
Tissue culture offers promise to oil palm breeders of being able to select 
individual plants each with a desirable combination of characters. The 
techniques of culturing oil palm are complex and need not be described. 
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Propagation by tissue culture offers the hope of combining high yields of palm 
oil together with a desirable fatty acid composition (Jones, 1983; Jones, 
1984). 
SOMACLONAL VARIATION 
At first it was assumed that all plants regenerated from the same parent 
plant by tissue culture would be identical clones. Such is by no means always 
the case. Plants arising from cell or tissue culture may possess markedly 
different characters, each from one another and from the parent plant from 
which the tissue was derived. It appears that while progressing from the 
original organized differentiated state in the parent plant, through the 
disorganized undifferentiated callus, then back to a newly organized 
differentiated state in the form of new plants, the chromosomes break up and 
the genetic code is reassembled in different sequences in each new plant. 
Being derived from somatic tissue these proqeny, genetically different 
from the parent cells, are described as somaclonal variants. Though 
uncontrollable and unpredictable they may offer a significant new source of 
genetic variability for plant breeders. In addition they may provide novel 
starting materials for the manufacture of new biologicals of economic value. 
NITROGEN FIXATION 
It is a popular misconception among journaliste that rDNA techniques now 
make possible the transfer from legumes to cereals of the genes which control 
symbiotic nitrogen fixation in the root nodules. Unfortunately, in legumes at 
least 17 genes (nif genes) are involved in the process of biosynthesizing 
protein from atmospheric nitrogen. The reduction of atmospheric nitrogen to 
ammonia in a living leguminous plant or in a chemical p'ant by the Haber Bosch 
or Cyanamid process absorbs large inputs of energy. The reduction of between 
12 and 15 moles of ATP is needed to provide the energy to reduce one mole of 
nitrogen in a legume nodule. The Haber Bosch process requires a pressure of 
1,000 atmospheres and temperatures of close to 6000C; the temperature of the 
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Cyanamid process is even higher. Even if the genes could be transferred, 
sequenced and induced to express themselves in a cereal grain, the energy used 
could very well show up in a significant reduction in total biomass yield. 
Also, unless the biochemical pathways in the cereal were appropriately 
modified, the increased nitrogen migh.t deposit itself elsewhere than in the 
seed. 
Much greater hope lies in the genetic manipulation of such nitrogen 
fixing bacteria as Rhizobia which cause nodules to form in legume roots where 
they convert atmospheric nitrogen to ammonia which the plant synthesizes into 
protein. Some success is also reported in the genetic manipulation of free 
living nitrogen-fixing soil bacteria by improving their association with the 
roots of cereal plants. 
The most widespread of the free living nitrogen-fixing organisms are the 
blue-green algae, some species being adapted to terrestial, others to aquatic 
conditions. Some survive in the Antarctic at near freezing temperatures, 
others above 600C in hot springs. The association between Anabaena azolla and 
the aquatic fern Azolla pinnata in tropical aquatic environments reportedly 
produces up to 150 km of nitrogen per hectare per year. The azolla is used to 
fertilize rice paddies or as forage for ducks and pigs. Naturally occurring 
heterotrophic nitrogen-fixing bacteria and blue-green algae can fix up to 50 
kg N/ha in submerged rice paddies that receive no nitrogen fertilizer. 
PROTOPLAST FUSION 
Bacterial DNA contains about 5,000 genes; a plant genome may contain 
anywhere up to 50 M genes of which less than 5% are actively synthesizing 
protein at any one time. Consequently, the genetic manipulation of higher 
plants is much more difficult than the transfer of expressive genes into the 
DNA of bacteria. However, as already stated, cells excised from any part of 
the plant: leaves, stems, roots, flowers, pollen, or buds, may be induced to 
propagate when dispersed and suspended in an appropriate nutrient medium. 
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Propagation is also possible from protoplasts: plant cells from which 
the cell walls have been removed mechanically or biochemically. Protoplasts 
may be subjected to experimental manipulations virtually impossible with 
intact cells. For example, protoplasts can take up foreign genes by 
microinjection. Protoplasts from different plants may be fused to produce 
hybrids unattainable by sexual crossing. Nevertheless, so far it has proved 
difficult in many species to regenerate whole healthy plants from 
protoplasts. Also, where whole plants have been derived from the 
hybridization of widely different genera, many have proven sterile and unable 
to reproduce thenselves. 
In addition to propagating plants from somatic vegetative tissue, cell 
fusion and tissue culture offer means of manufacturing secondary metabolites 
to be applied as insecticides, pharmaceuticals, fragrances, flavours and 
various other substances useful to food, pharmaceutical and other bioloqical 
industries. 
PLANT METABOLITES 
The plant breeder requires that tissue culture generate a shoot and a 
root. Plant metabolites of economic value may well be produced from 
undifferentiated cell cultures, only those cells which synthesize the 
metabolite being propagated. At present the industrial production of plant 
metabolites is constrained by a somewhat primitive state of the art and the 
high cost of production. It has been estimated that the end product must 
demand a price of at least $600/kg if production by tissue culture is to be 
economically feasible. Shikonin, an ingredient of cosmetics, is reportedly 
manufactured by the culture of Lithospermum cells in Japan. Other substances 
now extracted from wild or cultivated plants that are being considered for 
production by tissue culture include codeine, opium, jasmine, digitoxin, 
quinine and reserpine. 
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Theoretically, any plant metabolite can be manufactured by cell culture, 
the advantage being the relative freedom from the hazards of weather, 
parasites, pests and diseases to which the growing plant is always 
susceptible. It is evident however that large-scale factory production 
of important tropical plant derivatives by cell culture could have serious 
consequences for many developing countries. The adverse effect of high 
fructose corn syrup (HFCS) upon cane sugar production is indicative of the 
serious incursions upon tropical agriculture that similar biotechnologies 
might bring about in the future. 
Certain bacteria induce tumors in plants by inserting their bacterial DNA 
into the plant's chromosome by means of a vector called a tumor-inducing (Ti) 
plasmid. This knowledge has been applied to introduce into Ti plasmids genes 
which can then be transferred into a plant's genome. 
It is reported that a gene which conveys resistance to an extremely 
potent herbicide has been transferred in an expressive form into cereal 
grains. It is important to emphasize that the goal of this biotechnological 
exercise is not to provide a plant needing less herbicide but rather to 
proliferate plants that tolerate increased herbicide use and therefore 
stimulate a greater demand for the purchase and application of herbicides. It 
is not surprising that large manufacturers of herbicides and other 
agricultural chemicals are acquiring control of major seed companies. 
The difficulty of scaling-up from a laboratory flask to a large batch 
fermentor is familiar to anyone who has worked in a brewing, pharmaceutical or 
other fermentation industry. The rapidly growing interest in plant and 
microbial cell culture has therefore led to extensive investment in continuous 
processes that enploy immobilized cells or enzymes. 
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IMMOBILIZED CELLS AND ENZYMES 
Naturally occurring biochemical conversions by immobilized organisms are 
widely evident, particularly in oceans, lakes and other aquatic environments 
where bacteria, molluscs, micro and macro alqae attach thenselves to solid 
surfaces and metabolise nutrients absorbed from the passing currents. Of 
particular economic importance are such mollusc filter-feeds as oysters, clams 
and mussels which are motile only during their early stages of life. Attached 
to rocks or mangrove roots in the wild, or to rafts, racks or ropes in 
artificial culture, the molluscs filter their essential nutrients from the 
water which passes through them. 
Hundreds of carriers, attachments and reaction mechanisms are being 
examined in immobilizing living cells and enzymes for continuous biochemical 
conversions. The techniques can be crudely classified as (1) adsorption; (2) 
covalent attachment; and (3) entrapment. Combined systems may, for example, 
use covalent linking to strengthen weakly adsorbed or gel-entrapped materials. 
Quick vinegar - the conversion of ethanol into acetic acid by passing 
wine over wood chips carrying aceto-bacter - is one of the oldest examples of 
immobilization by adsorption. In 1916 invertase was successfully adsorbed 
onto charcoal and aluminum hydroxide to hydrolyze sucrose. Among the earliest 
industrial applications, immobilized amino-acylase from Aspergillus oryzae 
adsorbed onto a DEAE-Sephadex column was used to separate the L- and D- 
optical isomers from racemic mixtures of the chemically synthesized amino 
acid. 
Adsorption relies upon attachment by such reversible bonds as 
electrostatic attachments and Van der Waal's forces. The many adsorption 
carriers reported include clays, sand, diatomaceous earths, glass, mineral 
salts, metallic oxides, ceramics and various organic polymers. The 
unpredictability is illustrated by the highly variable behavior of lactase 
when immobilized into silica (Si02), and titanium oxide respectively. On 
silica the enzyme activity was significantly higher at pH 3 than at pH 7. On 
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titanium oxide the reverse was the case. At both pH levels enzyme activity 
was 3 to 4 times greater on titanium oxide than on silica. The average pore 
size of both carriers (ca. 370 Angstroms) was rouqhly the same. 
In spite of the research attention it has been given, immobilization by 
covalent cross-linking has gained relatively little commercial application. 
Reagents are generally expensive and those that are toxic to living cells are 
inadmissible for food, beverage and pharmaceutical processes. In many 
instances it is either not technically feasible or too expensive to regenerate 
the carrier. Nevertheless, the immense range of options among possible 
covalent attachments offers exciting possibilities for the future of 
immobilized catalysts. If ever the alternatives can be reliably and 
systematically brought together, a computerized decision tree would be a 
valuable aid to making reliable choices among them. 
Immobilization by entrapment depends upon the occlusion of an enzyme or 
celi within a hydrophobic gel, a polymer, a membrane or a fibre. Such systems 
accept only substrates and reaction-products relatively small in particle 
size. Materials reported upon include polyacrylamide gels, polyurethane 
foams, silastic and starch gels, acrylic resins and collagen. Entrapment is 
achieved by gelatinization, polymerization or coagulation of a solution or 
dispersion of the cell or enzyme in an aqueous medium. In fibre entrapment, 
the solution is extruded through a spinneret into a coagulant bath, similar in 
principle to processes used to manufacture nylon and texturized vegetable 
protein. 
Entrapment is attractive in that the catalyst exists in dispersed aqueous 
droplets. There being no chemical bonding, the integrity and stability of the 
cells and enzymes are relatively well preserved. On the other hand, control 
of pore size is critical and difficult. Pores that are too large permit 
leakage of the catalyst; pores that are too small or cells that are too 
densely packed will inhibit diffusion of the substrate solution and restrict 
reaction to the surface areas. 
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An attractive but relatively little exploited opportunity is to imprison 
living, actively metabolizinq microorqanisms in a porous matrix. Even mild 
toxicity of the medium of entrapment may not be an absolute constraint. For 
example, in the production of aspartic and malic acids, enzyme catalysis 
continues following mortality of the bacteria entrapped in polyacrylamide. 
Most widely publicized is the manufacture of High Fructose Corn Syrup, 
total annual production of which exceeds 3 M tonnes. In North America, HFCS 
has replaced more than 36% of the sucrose formerly used in industrial 
manufacturing. Though the conversion of glucose by immobilized 
glucose-isomerase is industrially well established, research to identify 
superior enzyme sources and more efficient continuous reaction systems is 
still in progress in several countries. 
In contrast, there seems little likelihood that the well established 
batch conversion of corn starch to glucose syrup, derived from the wet milling 
of maize, will give way to a continuous process employing immobilized alpha- 
amalyse and gluco-amylase. Both enzymes suffer impaired efficiency when 
immobilized and, despite the theoretically shorter conversion time in a 
continuous process, and the many attem pts at adsorption, covalent attachment 
and entrapment, the batch process remains commercially undisturbed. Thus, the 
manufacture of HFCS from corn starch will continue as a combined batch plus 
continuous process. 
Research efforts to immobilize lactase for the conversion of lactose in 
whey; rennet, pepsin and chymotrypsin for milk curd coagulation; catalane, 
glucose oxidase and sulphydryl oxidase for milk processing are too numerous to 
mention. With a few minor exceptions, none have yet achieved industrial 
viability. 
Annual amino acid production approaches half a million tonnes at a value 
close to US$1.25 B. About two-thirds are for human consomption, one-third for 
animal feeds. Japan supplies 90% of the world's amino acids. Glutamic acid, 
lysine, tryptophan, tyrosine, alanine and citrulline are all manufactured in 
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whole or part by immobilized enzymes or microorganisms. In this field, 
whether b y continuous biological or a combination of chemical and enzymatic 
reactions, the Japanese are ahead of most other nations and hold manufacturing 
patents for all 20 commercially available amino acids. 
Dominated by Japanese technology is the process whereby ribonucieic acid 
is hydrolized by immobilized RNAase to produce the mononucleotide flavour 
enhancers: inosine monophosphate (IMP) and guanosine monophosphate (GMP). 
For reasons undiscovered, these mononucleotides act synergistically with 
monosodium L-glutamate (MSG) in increasing the meaty flavour of soups, stews 
and sauces. The flavour enhancement of MSG is magnified 5-fold when mixed 
with 4% equimolar IMP/GMP. In Japan, RNA from yeast is continuously 
hydrolized by the RNAase of Penicillium citrinium adsorbed on a porous ceramic 
column. The adenosine monophosphate formed is converted by a microbial 
deaminase to IMP. 
BREWING 
Most food industries prosper by diversity: by continuously developing new 
products and processes for their manufacture. In contrast, the brewing 
industry has survived and prospered largely by improving the efficiency of 
production of its basic product: beer. Traditionally, beer is produced from 
malted cereals (mainly barley), yeast, hops and water, though only in the 
Federal Republic of Germany is beer brewing restricted by law to these four 
basic ingredients. 
Mechanization of the malting process began with Galland's pneumatic 
malting apparatus in 1885, followed by the Saladin box with screws to turn the 
malt and, more recently, the Wanderhaufen moving malting couch. Though the 
earliest recorded experiments began in the last century, continuous 
fermentation in brewing has not achieved wide industrial acceptance. Only two 
New Zealand breweries rely significantly upon continuous fermentation. 
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Stewart and Russell (1985) explain the failure of continuous fermentation. 
"Essentially, batch fermentation is simple; a vessel is cleaned, 
sterilized and rinsed; it is filled with wort and the required quantity 
of yeast is inoculated. The temperature cycle can be pre-programmed and 
little further attention is required until it is necessary for further 
processing, 3 or 4 days for an ale, 7 to 10 days later for a lager. 
Operation by trained but not highly qualified staff is straightforward. 
On the other hand, continuous fermentation requires constant laboratory 
monitoring and complex automatic control of flow rates, temperature 
gradients, yeast recycle and oxyqen levels. Cell morphology and 
fermentation gravity need regular checking. Engineering support to 
correct possible faults in control systems, pumps, heat exchangers and 
pasteurizers is required. All these must be available 24 hours a day, 7 
days a week. 
The much more rapid flow from continuous fermentation is, in part, an 
illusion. It is necessary to have a reservoir of wort to feed the 
fermentor. Because other types of beer are likely to be produced in the 
saure plant, a beer reservoir to accumulate the output into suitable 
batches for further processing is required. Although the residence time 
within the fermentor may be very short, this is not the economic factor 
that should be considered. It is the residence time in the plant that 
matters and this may be in excess of 24-36 hours. The use of continuous 
fermentation significantly reduces the flexibility of a brewery. Not all 
consumers drink the saure beer, they drink more in summer than winter, 
they drink more on a hot, dry weekend than on a cold wet one. An ability 
to provide the required diversity of products in varying and 
unforeseeable amounts is a prerequisite of a successful brewing 
operation. Batch fermentation can meet this need for flexibility far 
better than a continuous process, which is best suited to the production 
of a high volume product at an unvarying rate." 
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Recently research workers at the Japanese Kirin Brewery (Onaka, et al. 
1985) described how the time to brew beer of acceptable quality can be reduced 
from 8 days to one day. Partly fermented wort is pumped throuqh a column 
reactor packed with Saccharomyces uvarum immobilized in beads of calcium 
alginate. By controlling the oxygen content it is claimed that undesirable 
diacetyl precursors can be controlled to acceptable levels. It will be 
interesting to see if this novel process eventually translates into a 
commercially viable system. 
BIOTECHNOLOGY IN JAPAN 
Because of the aggressive and, in nome respects, unique approach the 
Japanese are taking in the world of biotechnology they deserve a special 
word. Food fermentation has been traditional in Japan for many centuries and 
it is probable that research on fermentation processes has been in progress 
for at least 100 years. Japan is the source of 21 of the 26 enzymes produced 
commercially and has accounted for at least 20% of all new antibiotics since 
1980. Of all the new pharmaceutical products introduced each year, in the 
early 1960s 24% originated in the United States, 10% in Japan. By 1983, 12.5% 
originated in the United States, over 35% came from Japan. 
The first paper on rDNA was presented in the United States in 1973; the 
first on a similar subject did not appear in Japan until six years later. 
Nevertheless, Japan's long history of traditional and industrial aerobic and 
anaerobic fermentations has enabled the Japanese to marshall a considerable 
army of experience, particularly in the design of large-scale bioreactors. 
These include 30-tonne capacity batch cultivation tanks and technologies based 
upon immobilized cells and enzymes. By applying their advanced engineering 
skills, combined with their highly developed sense of and experience in 
manipulating biological processes, the Japanese have quickly made up for lost 
time and are now at the world's leading edge of biotechnological development. 
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Japan's experience in traditional and industrial fermentations, including 
soya sauce, sake, and cell culture (Chlorelle), extends over many centuries. 
Large-scale industrial fermentations and enzyme conversions started before 
WWII. Industrial acetone-butanol fermentations were in progress in 1940, 
antibiotic manufacture by 1944; glutamic acid by fermentation replaced 
hydrolysis of wheat gluten in the mid-1950s and the flavor enhancing 
nucleotides have been produced industrially since the early 1960s. From that 
time the range of Japanese manufactured amino acids, antibiotics and other 
fine chemicals has rapidly expanded. 
The Japanese appear to consider biotechnology as their greatest 
technological hope for the future. Consequently, Japanese research and 
progress towards commercial ization of biotechnology is accelerating over a 
broad range of industrial enterprises, particularly in those companies with 
relevant bioprocessing experience. 
Unlike many other countries, the Japanese recognize what they are good at 
and have formulated a science policy with a clear concentration upon products 
derived from fermentation and related biotechnologies. Over the past 20 
years, as a percentage of total R&D expenditures on pharmaceuticals throughout 
the world, Japan has increased its world share from 6% to 15%. 
A major reason for the rapid progress made in Japan is that all 
government-financed research in national research laboratories and 
universities is directed by the Council for Science and Technology, the 
Chairman of which is the Prime Minister. The CST has commissioned several 
important studies including a basic plan for R&D in the life sciences which 
includes research objectives to improve the manipulation of materials carrying 
genetic information; and bioelectronics and biological materials as they 
relate to medicine, food, energy and other essential resources. In addition, 
the Japanese Ministry of International Trade and Industry (MITI) has 
established a research association for biotechnology to encourage research 
cooperation among 14 Japanese companies in technological development related 
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to the large-scale utilization of genetically manipulated plant and microbial 
cells. They appear as world leaders in the design and development of 
bio-reactors. 
Japanese companies are now spending over $200 M annually on 
biotechnology research, about one-quarter of which is on genetically 
manipulated cells. The diversification of Japanese industries with experience 
in fermentation technologies into pharmaceuticals is worthy of special note. 
New or significantly expanded R&D in pharmaceuticals include chemical 
companies such as Hitachi and Mitsubishi; food and beverage industries 
including Ajinomoto, Suntory and Kirin Brewery; and textile and pulp companies 
such as Ashi and Toray. The cross-over integration of chemicals, food and 
drugs demonstrates a philosophy of growth from technological know-how rather 
than from a base of established markets. 
The U.S. clearly regards Japan as its mort formidable competitor in 
industrial biotechnology. Though, in absolute amounts, U.S. companies make 
greater investments in research and display more marketing muscle on an 
international commercial scale, the Japanese have gained the leading edge in 
industrial fermentation technologies and possess a higher proportion of 
trained bioengineers relative to their needs than either the U.S. or most 
European countries. Japanese companies place technical staff overseas as 
intelligence gatherers. About 20% of Mitsui's technical development staff are 
based in other countries. 
During the 1970s, Japanese companies innovated more new drugs, mainly 
antibiotics, than any of their international competitors. In light of their 
falling profits during the past year, caused largely by increased prices and 
reduced government subsidies for drugs distributed in Japan, Japanese drug 
companies are now moving up-market to develop interferons, cardiovascular 
and similarly high-priced drugs. 
Though they supply 85% of drugs purchased in Japan, being younger in 
origin, the Japanese pharmaceutical companies possess a narrower experience 
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and a smaller world market share than, for example, Hoffman la Roche, Merck 
and Glaxo. The Japanese drug companies are now moving quickly to increase and 
diversify their R&D expenditures; some by creating new research facilities in 
Japan, sonie by financing research in other countries. For example, Otsuka is 
setting up research facilities in Maryland; Ajinomoto proposes to invest 
US$3.8 M in cancer research at MIT. About 40 Japanese companies have 
established formal arrangements with bioscientific enterprises overseas in the 
hope of licensing new products to their larger U.S. and European partners. 
Japanese, Chinese and other oriental language data bases are better 
designed to admit accessions from western language publications than are 
Am erican and European data bases to admit entries published in oriental 
ideographic languages. Since, also, the Japanese make greater efforts to 
learn English than Anglophones make to learn Japanese, they gain better access 
to our publications than we to theirs. UMIST's Centre for Computational 
Linguistics has been awarded a major grant for the design and implementation 
of a prototype English-Japanese translation system. It is to be hoped it will 
accommodate Japanese to English translation. 
Though Japanese industry invests significantly more than the government 
in biotechnology R&D, the government's clearly defined science and technology 
policy, support for universities in related research, protective licensing and 
import regulations all serve to stimulate Japanese industrial biotechnoloqical 
development. It is estimated that the total value of industrial 
microbiological products made in Japan is US$50B or close to 5% of GNP, only 
slightly less than the total value of Japanese electronic equipment. 
Japanese industries are less dependent than those in the U.S. upon 
venture capital. Most Japanese biotechnology companies have at least one bank 
as a major shareholder which provides low interest bans for R&D. The 
government encourages such financial institutions to establish long-term 
relations either by equity investment or favourable bans. 
Over the past decade, in almost all industrialized countries, investment 
in R&D by private enterprise has outstripped that by governments. The sad 
exception is Britain where, since 1981, industrial support for R&D has 
continued to decline. A recent survey by Mori brings to light a striking 
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contrant between Japan and most other countries, particularly Britain, in the 
way private companies keep abreast of technological development. Almost 
one-third of Japanese companies have on their boards a scientifically 
competent person whose specific responsibility is technological development. 
In sharp contrast, company directorates which include scientiste specifically 
responsible for advising on technology are roughly one out of every eighteen 
in the U.S. and one in every thirty British companies. 
The Japanese intend to maintain and expand their superior cadre of 
scientists and technologists in the biosciences. There are close ties between 
Japanese industry and universities who willingly undertake applied research. 
Recognizing their comparative weakness in basic sciences such as molecular 
biology and immunology, the government and the major biotechnological 
companies sponsor and support overseas training for young Japanese scientiste. 
Though the Japanese maintain a careful cloak of secrecy over their more 
important industrial activities, some trends are evident. They are focussing 
upon protein engineerinq: new proteins synthesized by qenetically modified 
cells and controlled chemical reactions. Results from crystallography, DNA 
hybridization and other analytical probes are fed to computers to determine 
amino acid configurations in existing proteins and to simulate models of 
protein structures with desirable functional properties. From computer models 
they hope to synthesize enzymes with three-dimensional structures tolerant to 
heat and aikalies. 
Another objective is to synthesize enzymes able to biodegrade stable 
pesticides such as DDT. A computer determines the optimum sequence of amino 
acids then programs the nucleotide alignment in the DNA necessary to generate 
the enzyme. The ultimate goal is to introduce this rDNA into a receptive 
microorganism which, after multiplication would be dispersed over soils 
bearing heavy residues of DDT. Recognizing that lignocellulose is the most 
abundant and under-utilized source of biomass, they are examining microbial 
and enzyme conversion of cellulose and lignocellulose into edible and 
functionally useful carbohydrates. 
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Increasing investments in the life sciences include research on 
oncogenesis and upon phenomena related to aging, includinq protein metabolism, 
chromatine structures, cellular degeneration and abnormalities, 
neuro-transmitters and the hormonal control of brain and nervous systems. One 
of the most novel potential applications of biotechnology relates to the 
Japanese electronics industry. Biochips are semi-conductors consisting of 
specific organic molecules surrounded and stabilized by specially designed 
protein mono layers. Possible applications of biochip implants include the 
regulation of heartbeats, the control of insulin release in diabetics and the 
controlled functioning of artificial limbs. 
The Japanese clearly intend to remain at the leading edge of 
biotechnological innovation and industrialization. 
BIOTECHNOLOGY IN THE UNITED STATES 
In the U.S., favorable tax incentives encouraged the rapid establishment 
and early growth of biotechnology research enterprises. The first venture 
capital was supplied to groups of university entrepreneurs in expectation of 
rapid and profitable exploitation of genetic engineering. When the early 
promise of rapid return was not realized, private venture capital became more 
difficult to attract and the biotechnology research enterprises had to seek 
support from industrial corporations. 
Having inadequately determined the time and resources needed to realize 
market opportunities and failing to generate adequate cash flow, many of the 
new biotechnological research enterprises did not survive. The survivors are 
mainly those that have integrated with commercial industrial organizations. 
These alliances ensure a more reliable source of research capital together 
with intelligence from market research and feedback from the factory floor, 
all of which are essential if applied research is to progress to a profitable 
conclusion. 
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Many of the pioneers were overly optimistic in their expectations of when 
profitable products would corne to the marketplace. Those that have survived 
may profit less from their reserch than the large multinational pharmaceutical 
and chemical companies with whom they have been forced to ally themselves. 
Between 1977 and 1983 these new bioscientific enterprises attracted more than 
US$350 M for research. Venture capital for scale-up and to create 
manufacturing and marketing facilities has been more difficult to corne by and 
few of the original research enterprises seem likely to metamorphose into 
manufacturing and marketing companies in their own right. 
Though the Japanese may remain up front in technological innovation, the 
U.S. companies will continue to dominate the marketplace. The U.S. is by far 
the largest consumer of pharmaceutical products and American companies 
dominate the U.S. market. Also, because of their large marketing forces and 
the high proportion (about 12%) of sales income devoted to R&D, the U.S. 
companies will remain sturdy defenders of their established markets. 
A development which cannot be ignored is the demand and supply of 
scientists and engineers in the U.S. Strategic Defence Initiative (SDI), or 
Star Wars research in its demotic title. Defence represents 70% of total 
U.S. Government R&D expenditures. The comparable figure in Japan is 1.0%. 
Star Wars will inevitably increase defence R&D and by 1990 may absorb over 13% 
of all U.S. Government R&D expenditures. Equally serious is the human 
resource demand. By 1987, more than 18,000 scientists and engineers will be 
employed in SDI R&D. Recognizing the power of military influence, the excess 
of demand over supply may well lead to a serions brain drain from both U.S. 
and other nations' professional human resources. 
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THE ROLE OF AND RELATIONS WITH UNIVERSITIES 
The patterns of biotechnoloqy have led to new relations between 
university science faculties and private industry. With the possible 
exception of applied engineering faculties, universities have generally 
embraced the philosophy that "academic science must be pure and above 
utilitarian considerations" as a recent Canada Science Council study (1982) so 
stated. For the most part, universities prefer government grants, free of 
conditions that constrain intellectual curiosity and the freedom to publish. 
In recent years, in mort Western nations government support of basic research 
in universities has steadily declined. Governments and the public alike 
appear less friendly to universities, the contemporary attitude being that 
academics should earn their keep by producing things which industry and the 
community can profitably use. 
Much of the best expertise in molecular biology and cell biochemistry 
resides within academic walls. As described earlier, the promise of rich 
rewards has encouraged many biologists to transfer their talents from academia 
to commercial research enterprises. North American universities are hustling 
to attract profitable liaisons with the industriel sector throuqh consultinq 
arrangements and industrial associate programs. In return for a fixed annual 
fee, the companies' scientists participate in specially organized seminars, 
have regular contact with faculty and graduate students and are permitted 
first access to research results and publications. 
Research contracts and research partnerships between industries and 
universities bear significant implications for the control of intellectual 
property. The research supported in universities by private industry will 
likely be of a more fundamental nature than the companies would carry out in 
their own laboratories. Since pharmaceutical companies are in business to 
make money and not simply to make drugs, they will expect some significant 
return on their investment. U.S. companies are awarding substantial contracts 
to universities. Washington University and Monsanto have established a five-year 
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renewable contract for US$23.5 M, about 30% of which will be for "fundamental 
research" and 70% for "special research directly applicable to human disease". 
Canadian universities are formulating strategies and creating 
administrative units to rationalize relations and cooperative ventures with 
the industrial sector. Guidelines are written to ensure that industrial 
cooperation is consistent with established academic programs and neither 
compromises the universities' moral standards nor inhibits its freedom to 
function impartially and in the best interests of the general public. 
HUMAN RESOURCES 
Since most government and industrial investment in bioscientific research 
is devoted to the health sciences, food science and technology is at an 
evident disadvantage in competing for an inadequate supply of competent 
people. The strain is likely to be particularly severe in bioengineering. 
Though the proportions vary among universities, less than 10% of Canadian food 
science students progress beyond their first degree into post-graduate 
studies. A small proportion of these will likely pursue research in 
bioengineering. A sufficient supply of people trained in scale-up of 
biotechnological processes; heat and mass transfer; a comprehensive 
understanding of fundamental and applied biological and physical engineering 
principles is not apparent in Europe or North America. 
LEGAL AND SAFETY REGULATIONS 
This year marks the tenth anniversary of the Asilomar Conference - an 
historic meeting of concerned scientists, from institutions throughout the 
world, who gathered in 1975 to discuss the safety and advisability of 
continued research in the emerging field of rDNA technology. 
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Their primary concern was the possibi1ity of experimental, 
genetically engineered organisms escapinq from the laboratory to the 
possible danger of people and the environment. The 140 or so 
participants agreed by the end of the meeting that rDNA research should 
be continued under two kinds of voluntary safety guidelines. First, that 
the experiments should be conducted in containment facilities consistent 
with the possible hazards; second, that the experimental organisms used 
should be so weakened as to have little chance of surviving outside the 
laboratory. Magnin (IDRC 1985) poignantly describes the difficulties 
attendant upon scale-up of dubious organisms: 
"The safety aspects of process scale-up are especially serious when 
working with pathogens. Equipment on the scale needed is not 
designed to fit with containment hoods; the building is in effect 
the hood, and the production staff must work within it. Pilot plant 
staff are not necessarily the same people involved in the basic 
research. The former are usually perlons more used to solving the 
many practical problems arising daily. Experienced perlons are 
difficult to find and are in high demand." 
The legal rights to patent products of biotechnology are somewhat 
obscure, particularly in the pharmaceutical field. Conventional drugs 
can generaily be protected by patents against imitation. Many of the 
first generation of drugs from biotechnology are mass-produced proteins 
closely similar to those that occur naturally and there seems to be 
increasing doubt as to whether they can be exclusively owned. The large 
industrial giants seem indisposed to go to court over claims to exclusive 
rights of, for example, particular types of interferons. As The 
Economist (1985) pointed out: 
"The first round of (biotechnological) products are not block 
busters. Genetically engineered interferons have disappointed in 
clinical trials and caused side effects...Rather than wastinq money 
on lawyers to try to protect patents on such products, biotechnology 
firms ought to think about ways of improving and cross licensinq 
technology. The microelectronics industry did this at a similar 
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stage in its development and oves much of its subsequent success to its 
sharing, at a price, the rights to innovation and processes. It seems 
possible that the second and third generations of biotechnologically 
derived pharmaceuticals may be sufficiently novel to be as patentable as 
are conventional pharmaceuticals." 
Government regulations that relate to health, safety and environmental 
protection and to the laws which govern intellectual property vary 
considerably amonq developed nations. Inconsistency among nations is 
particularly evident in regulations that govern the deliberate release of 
genetically transformed organisms into the environment. 
Patent laws among countries differ on the types of biotechnological 
inventions that may be protected. For example, the United States permits 
patents for living organisms including plants and possibly animals, their 
products, components, methods for making or using all of them and for 
therapeutic and diagnostic methods. In the U.K., the FRG, France, Switzerland 
and Japan, patents are not permitted on plants, animals, therapeutic or 
diagnostic methods. 
The ultimate and eventual control of the exploitation of intellectual 
property remains obscure. The greatest danger of a shift of genetic 
engineering of crop plants from the public to the private sector is that the 
techniques and varieties formerly embraced and retained in the public domain 
will become patented and proprietary. Plant varieties and the tools of 
genetic engineering, including genes themselves, could become protected by 
laws and patents. In the future, it might corne about that farmers are not 
permitted to reproduce germplasm from their own plantations if their crop 
genotypes included a gene that at some stage had been patented by a 
multinational corporation. 
Historically, qenetic mutations within living organisms brought about by 
natural processes have evolved in a subtle and relatively slow manner. 
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Consequently, not until the advent of food irradiation were regulatory 
authorities required to give serious thouqht to genetic mutation and the 
potential hazards of the novel and often unpredictable products of free 
radical reactions. 
The potential impact of induced alterations in DNA nucleotide sequences 
and gene cloning seriously upsets the regulatory agencies' gradual and 
methodical adjustment to evolutionary change. In the US FDA category of food 
ingredients "generally recognized as safe by experts qualified by training and 
experience to judge their safety" (the GRAS category) "safe" is defined as 
exhibiting "reasonable certainty of no harm". The new techniques of genetic 
manipulation are proceeding at a rate that precludes parliaments and 
regulatory aqencies from following their normal leisurely approach to the 
attendant issues of comparative safety. 
Late in 1984 the Office of Science and Technology Policy (OSTM published 
the U.S. Government's policies towards biotechnology. The document, which is 
51 pages long, describes as its purpose: "to provide a concise index of U.S. 
laws related to biotechnology; to clarify the policies of the major regulatory 
agencies that will be involved in reviewing research and products of 
biotechnology; to describe a scientific advisory mechanism for assessment of 
biotechnology issues; to explain how the activities of the federal agencies in 
biotechnology will be coordinated". It goes on to state that biotechnology 
will be regulated in a manner that will not "stifle innovation and impair the 
competitiveness of U.S. industry". 
Many concerns about safety have been raised, including the possible 
effect of genetic manipulations on the potential virulence of altered 
microorganisms and the ability of new and potentially harmful organisms to 
obtain selective advantages. It has been noted that the molecu'iar structure 
of some biotechnologically derived drug products are different from those of 
the naturally occurring active molecules. To determine to what degree these 
differences in chemical composition will affect biological activity or 
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immunogenicity calls for extensive chemical and biological testinq prior to 
licensing. When a genetically modified microorganism is used to produce a 
traditional and familiar end product more efficiently it will be necessary to 
ensure that it does not simultaneously produce unfamiliar and unusual 
by-products. 
Following publication of the OSTP's policies on biotechnology, 
Congressman John Dingell stated that he intends to preside over a thorough 
review of the adequacy of all the laws applicable to biotechnology; and how 
they will be interpreted and applied in the implementation of biotechnology 
programs. Cell fusion, embryo transplants and elaborate gene transfers may 
eventually give rise to intergeneric plant hybrids and animal chimeras widely 
different from plants and animals currently inspected under established food 
and druq regulations. Decisions will have to be made as to what extent such 
wide intergeneric hybrids must be regarded as novel foods requiring new 
regulatory protocols. 
NOVEL FOODS 
The safety of novel foods is being addressed by specialist committees in 
the United States, the United Kingdom and several other countries. Particular 
attention must surely be given to novel foods derived from fermentation of 
unusual raw materials, such as lignocellulose degraded by lignocellulytic 
funghi and other microorganisms quite unfamiliar to human diets. Any 
suggestion that novel fermentation products should supplement the diets of 
poor people in developing countries, debasing them to the status of 
experimental guinea piqs for the rest of mankind, is surely unworthy of 
responsible consideration. 
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RESPONSIBLE MANAGEMENT 
On the last occasion I was privileged to speak to the North of England 
Branch of the IFST, I expressed concern with contemporary trends in ownership 
and management of food corporations (Hulse, 1984). Antipathy towards research 
and technological development is evident among accountants whose vision 
reaches only to the bottom line of the latent financial statement: those who 
regard research as an expense, not as an investment. Particularly worrisome 
are the financiai holding corporations which acquire assortments of 
technologically unrelated companies and manage them as they would a stock 
portfolio. The strength of Japanese industry lies in its commitment to 
research and its disposition to promote scientists and technologists to senior 
management positions. 
The traditional fermentation industries: baking, brewing and dairying, 
were created by craftsmen with an intimate understanding of their trade. With 
pragmatic cognizance of their constraints they were better able to assess 
their opportunities than were accountants and corporate lawyers. 
It was Montesquieu who wrote: "Success depends upon knowing how long it 
takes to succeed." The short history of the new biotechnologies makes it 
exceedingly difficult to give reliable forecasts of technological 
fulfillment. Such forecasts are beyond the ken of corporate accountants and 
lawyers. Sadly, the vision of many research scientists does not extend far 
beyond the laboratory door. The future of the food, pharmaceutical and 
related biotechnological industries requires a new breed of management: 
people who can conceive and integrate the total complement of resources needed 
to successfully develop, manufacture, and safely and economically distribute 
the products of biological innovation. To provide this essential new clans of 
scientific managers presents a unique, and one would hope, stimulating 
challenge to all universities. 
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Thoreau wrote: "He is not a true man of science who does not bring human 
sympathy to his studies." The Book of Proverbs counsels that "without vision 
the people will perish". 
Guided by a new and carefully cultivated group of men and women who 
combine scientific management with a vision refined by human sympathy, the 
emerging biotechnologies may benefit mankind immeasurably. But in incompetent 
or irresponsible hands the outcome will be at best disappointing; at worst 
disastrous. 
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